Please login to the form below

Not currently logged in
Email:
Password:

cell therapy

This page shows the latest cell therapy news and features for those working in and with pharma, biotech and healthcare.

FDA expecting boom in cell and gene therapies

FDA expecting boom in cell and gene therapies

The last couple of years have already seen the approval of the first gene therapy in the US – Spark Therapeutics’ Luxturna for a rare disease – as well as new cell therapies ... Taken together, these guidance documents, along with other policies

Latest news

More from news
Approximately 5 fully matching, plus 216 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    Cell therapy products based on antigen presenting cells. for target‐specific killer CD8 T‐cell responses. ... Manufacture and supply of CAR‐T cell therapy, Kymriah, for B‐cell acute lymphoblastic leukaemia.

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    Pfizer also has a considerable stake in one of the most exciting emerging areas of innovation, cell and gene therapy. ... It has gene therapy deals with Spark in haemophilia and with Sangamo in ALS.

  • Regeneron and Bluebird sign $100m cell therapies deal Regeneron and Bluebird sign $100m cell therapies deal

    Six targets chosen from TCR and other cell therapy platforms. ‘Big biotech’ Regeneron and cell and gene therapy specialists Bluebird Bio have unveiled a new collaboration which gives both greater presence ... peptides, while Bluebird will contribute

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    The development of its sickle cell therapy and beta thalassemia has been the epitome of the biotech rollercoaster, with very promising results in one sickle cell patient raising hopes, then failing ... At EHA people already had expectations in

  • The NHS and ABPI at 70: inching closer to the triple win The NHS and ABPI at 70: inching closer to the triple win

    Meanwhile, the pharma industry is hitting new heights in drug innovation, including cures for diseases such as hepatitis C, haemophilia and huge progress in cancer and cell and gene therapy - but ... This, and near-perpetual reform, continues to confound

More from intelligence
Approximately 0 fully matching, plus 30 partially matching documents found.

Latest appointments

  • Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult and more Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult and more

    Ceylad appoints new CFO. Clinical-stage biopharma focused on the development of CAR-T cell therapies has announced that Filippo Petti has been appointed as Chief Financial Officer. ... He said: “Celyad’s differentiated approach to the field of CAR-T

  • Industry appointments Industry appointments

    Rogerio Vivaldi leaves Bioverativ buyout to head up Sigilon. US-based biotech Sigilon aiming to deliver stem cell therapies for diabetes is getting a new leader. ... In the longer term, Hassan will lead research activities with the aim to expand

  • Weekly industry appointments Weekly industry appointments

    GSK’s CSO cell and gene therapy heads for the exit, Gelesis adds to company, Abcam appoints Peter Allen and Joseph Swedish joins Mesoblast’s board. ... be a global leader in the development and commercialisation of cell and gene therapy treatments.”

  • Zelluna Immunotherapy appoints chief technology officer Zelluna Immunotherapy appoints chief technology officer

    Arjan Roozen, who previously headed up the GMP solutions and manufacturing team at French cell therapy group Cellectis, comes with expertise in microbiology and molecular microbiology. ... Miguel Forte, chief executive officer of Zelluna, said:

  • Bone Therapeutics strengthens board with new chairman Bone Therapeutics strengthens board with new chairman

    Jean Stéphenne joins the cell therapy company from TiGenix. Belgian biotechnology company Bone Therapeutics has appointed Jean Stéphenne as its new chairman of the board of directors, succeeding Steve Swinson in ... He will be a valuable addition to an

More from appointments
Approximately 1 fully matching, plus 27 partially matching documents found.

Latest from PMHub

  • Highlights in haematologic malignancy from ASH 2018

    The spotlight shone on Chimeric Antigen Receptor(CAR) T-cell therapy; a transformative approach where the patient’s T cells are harvested and re-engineered to recognise antigens expressed by the ... A reduced risk of relapse was also seen when

  • Random42 attending Biotech Showcase in San Francisco

    Alzheimer’s Disease. Cell and Gene Therapy. Immuno-Oncology. NASH (Nonalcoholic steatohepatitis). Rare and Orphan Diseases.

  • Solaris Health looks at the gene therapy revolution

    And every new therapy will have its own specific challenges depending on the disease it is targeting. ... As an example, in the case of Strimvelis (autologous CD34. cells transduced to express adenosine deaminase [ADA]), the first ex vivo stem cell gene

  • Training the next generation of biotech leaders

    As a result, he is at the forefront of inspiring the next generation of scientists to make breakthroughs in cell and gene therapy. ... It brings engineers and people from the life sciences sector into the department to learn about biochemical engineering

  • Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies

    Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the ... You have this fantastic jewel that nobody really noticed but in the

More from PMHub
Approximately 1 fully matching, plus 10 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics